CONTACT US
Home > Metabolic Enzyme/Protease>HMG-CoA Reductase (HMGCR)> > Rosuvastatin
287714-41-4-Rosuvastatin Rosuvastatin

Rosuvastatin

For research use only. Not for therapeutic Use.

  • CAT Number: I002987
  • CAS Number: 287714-41-4
  • Molecular Formula: C₂₂H₂₈FN₃O₆S
  • Molecular Weight: 481.54
  • Purity: ≥95%
Inquiry Now
Related products: 2-Hydroxy-4-methoxybenzaldehyde     Quinidine sulfate     C2 Ceramide    

Rosuvastatin（Cat No.:I002987）is a potent statin used to lower cholesterol levels by inhibiting HMG-CoA reductase, the enzyme responsible for cholesterol biosynthesis in the liver. It is commonly prescribed to reduce the risk of cardiovascular diseases, such as heart attacks and strokes, by lowering LDL cholesterol and raising HDL cholesterol. Rosuvastatin also has anti-inflammatory and plaque-stabilizing effects, contributing to its protective role in atherosclerosis management. Its high efficacy and favorable safety profile make it a widely used option for managing hyperlipidemia and reducing cardiovascular risks in patients.


Catalog Number I002987
CAS Number 287714-41-4
Synonyms

(E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid

Molecular Formula C₂₂H₂₈FN₃O₆S
Purity ≥95%
Target HMG-CoA Reductase
Solubility 10 mM in DMSO
Storage Store at -20℃
IC50 11 nM
IUPAC Name (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid
InChI InChI=1S/C22H28FN3O6S/c1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32/h5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30)/b10-9+/t16-,17-/m1/s1
InChIKey BPRHUIZQVSMCRT-VEUZHWNKSA-N
SMILES CC(C)C1=NC(=NC(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)N(C)S(=O)(=O)C
Reference

<p style=/line-height:25px/>
<br>[1]. Watanabe, M., et al., Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem, 1997. 5(2): p. 437-44.

<br>[2]. Schneck, D.W., et al., The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther, 2004. 75(5): p. 455-63.

<br>[3]. Kim, Y.S., et al., Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells. J Cardiovasc Pharmacol, 2007. 49(6): p. 376-83.

<br>[4]. Carswell, C.I., G.L. Plosker, and B. Jarvis, Rosuvastatin. Drugs, 2002. 62(14): p. 2075-85; discussion 2086-7.

<br>[5]. Stalker, T.J., A.M. Lefer, and R. Scalia, A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol, 2001. 133(3): p. 406-12.

</p>

Request a Quote